Navigation Links
Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis
Date:2/2/2008

y, experienced at least one AE, compared with 56 and 48 percent of patients switched to placebo. Serious AEs were observed in 0 and 1 percent of patients continuing treatment with 45 mg and 90 mg ustekinumab, compared with 0 and 2 percent of patients switched to placebo.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease, which results from the overproduction of skin cells, resulting in their accumulation on the surface of the skin, which causes red, scaly plaques that may itch and bleed. It is estimated that approximately 7.5 million people in the United States and 10 million Europeans are living with psoriasis and nearly one-quarter of those people have cases that are considered moderate to severe.(1)

About Ustekinumab

Ustekinumab is a new, human monoclonal antibody in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis, and is being investigated as an infrequently administered subcutaneous injection. Ustekinumab is a novel biologic therapy that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that are important in regulating the immune system and that are also believed to play a role in immune-mediated inflammatory disorders.

Centocor discovered ustekinumab and has exclusive marketing rights to the product in the United States. Janssen-Cilag companies have exclusive marketing rights in all countries outside of the United States. Centocor, Inc. and the Janssen-Cilag companies are members of the Johnson & Johnson family of companies.

About Centocor, Inc.

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.

The world leader
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
2. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
3. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
4. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
5. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
6. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
7. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
8. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
9. Inverseon Announces Positive Phase IIa Asthma Study
10. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
11. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Decline in Global Measles Deaths, Joint News Release: ... and WASHINGTON, Nov. 29, Measles deaths in Africa fell ... 396,000 to 36,000, reaching the,United Nations 2010 goal to ... spectacular gains achieved in Africa helped generate a strong,decline ...
... Nov. 29 AIDS Action Council,joins organizations and individuals ... 20th annual World AIDS Day, December 1, 2007. Since ... awareness,about the HIV/AIDS pandemic and to reinvigorate global, national, ... and 2008 theme of World AIDS Day is leadership. ...
Cached Medicine Technology:Measles Deaths in Africa Plunge by 91% 2Measles Deaths in Africa Plunge by 91% 3Measles Deaths in Africa Plunge by 91% 4AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic 2
(Date:7/10/2014)... 3 fatty acids had healthier joints than those fed ... acids, according to Duke Medicine researchers. , The findings, ... (10.1136/annrheumdis-2014-205601) on July 11, 2014, suggest that unhealthy ... to worsening osteoarthritis. , "Our results suggest that dietary ... in the link between obesity and osteoarthritis," said Farshid ...
(Date:7/10/2014)... 10, 2014 Ticketability.com has a wide array ... Paul McCartney tickets for San Diego are being added to ... since 1976, and the newly added September 28 show is ... Click Here to view the selection of discounted ... Park will become available to the general public on July ...
(Date:7/10/2014)... York, US (PRWEB) July 10, 2014 ... , Merrill DataSite recently streamed the live webinar ‘Capitalizing ... a discussion from a group of several M&A experts ... seeing in the broader energy transaction marketplace. These experts ... and how the deal market in this sector has ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 In his ... speaker and drug treatment facility CEO Per Wickstrom has ... “Whether we’re trying to confirm an appointment, get information ... is that following-up without being annoying is a skill ... there is a way to keep the dialogue moving ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Parker ... protecting the rights of victims injured by defective ... a lawsuit over allegations that the woman’s hidden, ... a power morcellator used during a routine laparoscopic ... against Richard Wolf Medical Instruments Corporation over its ...
Breaking Medicine News(10 mins):Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Paul McCartney Tickets for San Diego: Ticketability.com Announces Discounted Tickets for McCartney’s Tour Stop at Petco Park on September 28 2Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5
... Ill., Nov. 15 Winston,Laboratories, Inc., a specialty ... products for pain management, and Getting,Ready Corporation (OTC ... operations, have signed a merger agreement that will ... company will be renamed,Winston Pharmaceuticals, Inc., and will ...
... International,Technology Inc. (MDLH. PK) ( http://www.mitcanada.ca , http://www.mitinvest.ca ... completed its,10QSB quarterly reports (December 2006, March 2007 ... with its filings. Medical International Technology Inc. ... means to help prevent the spread of deadly ...
... can lead to under-reporting when applying for driver,s licenses, ... In patients with focal epilepsy, simply asking how often ... their seizure frequency, German research suggests. , Reminding patients ... help, either, because they may be unaware of some ...
... simplex virus type 2 (HSV-2) and HIV revealed that drugs ... the blood and rectal secretions, which may make patients less ... in the November 15 issue of the Journal of Infectious ... are also infected with HSV-2, which is the major cause ...
... year due to ... lung cancer --, -- More than 50% of new patients have ... according to the Lung Cancer Alliance --, ... early cancer detection, and The Thomas,G. Labrecque Foundation, a nonprofit organization that funds lung ...
... and Free Test Kits at the Radisson in Celebration, ... are,invited to a free Alpha-1 Education Day on Saturday, ... Radisson Resort Orlando - Celebration, located at,2900 Parkway Blvd. ... one of the most common,life- threatening genetic disorders, but ...
Cached Medicine News:Health News:Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement 2Health News:Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement 3Health News:Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement 4Health News:Some Epilepsy Patients Not Always Aware of Seizures 2Health News:Study shows suppressing herpes virus may reduce infectiousness of HIV 2Health News:Canary Foundation and the Thomas G. Labrecque Foundation Launch a New Lung Cancer Early Detection Initiative 2Health News:Canary Foundation and the Thomas G. Labrecque Foundation Launch a New Lung Cancer Early Detection Initiative 3Health News:Canary Foundation and the Thomas G. Labrecque Foundation Launch a New Lung Cancer Early Detection Initiative 4Health News:Free Program Dec. 1 to Help Patients With Debilitating Pulmonary Disorder Alpha-1 2
300 L, Racked, 96 tips/rack Recommended for 250 and 300 L pipettes....
... tips in a rack for single- ... of Autoclavable Racks: Can be steam ... in racks with an 8 x ... tips is specifically designed to ensure ...
RNase-free Tips...
... tips in a rack for single- ... of Autoclavable Racks: Can be steam ... in racks with an 8 x ... tips is specifically designed to ensure ...
Medicine Products: